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Abstract
Purpose: To evaluate the efficacy of portal vein embolization (PVE) with n-Butyl-cyanoacrylate (NBCA) through
an ipsilateral approach before major hepatectomy. Secondary end-points were PVE safety, liver resection and
patient outcome.
Methods: Over a 5-year period 50 non-cirrhotic consecutive patients were included with primary or
secondary liver cancer treatable by hepatectomy with a liver remnant (FLR) volume less than 25% or less than
40% in diseased livers.
Results: There were 37 men and 13 women with a mean age of 57 years. Colorectal liver metastases were
the most frequent tumor and patients were previously exposed to chemotherapy. FLR increased from 422 ml
to 629 ml (P < 0.001) after PVE, corresponding to anincrease of 52%. The FLR ratio increased from 29.6% to
42.3% (P < 0.001). Kinetic growth rate was 2.98%/week. A negative association was observed between
increase in the FLR and FLR ratio and FLR volume before PVE (P = 0.002). In 31 patients hepatectomy was
accomplished and only one patient presented with liver insufficiency within 30 days after surgery.
Conclusions: PVE with NBCA through an ipsilateral puncture is effective before major hepatectomy.
Meticulous attention is needed especially near the end of the embolization procedure to avoid complications.
Trial registration: Clinical Study ISRCTN registration number: ISRCTN39855523. Registered March 13th 2017.
Keywords: Portal vein, Embolization, Future liver remnant, Extended hepatectomy, Hepatic insufficiency
Background
More than 30 years after its first publication, portal vein
embolization (PVE) is still abundantly used to successfully
promote hepatic hypertrophy before major hepatectomies
[1]. Hepatic resection is currently the cornerstonein the
curative treatment of primary liver malignancies such as
cholangiocarcinoma, hepatocellular carcinoma and metas-
tasis from colorectal cancer and other primary origins [2].
To allow hepatic resection most hepatobiliary services
admit a future liver remnant (FLR) of at least 25% in
healthy livers [3]. For diseased livers, as in heavily chemo-
therapy treated patients [4, 5]or in hepatic cirrhosis candi-
dates [6], larger FLR of 35% to 40% are required.
Embolization of the aimed portal vein territory will diverge
all blood flow containing trophic and growth factors to the
FLR, inducing hypertrophy and permitting the prearranged
future surgery [7]. As with PVE, liver surgery greatly
evolved over the years allowing more patients to undergo
this potentially curative treatment [8, 9]. Systemic chemo-
therapy additionally played an important role downsizing
tumors and converting previously unresectable patients
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into surgical candidates [10]. PVE has been shown to besafe
and effective in promoting FLR growth [3, 11] and is cur-
rently adopted in the preoperative scenario in many hepa-
tobiliary units worldwide [12].
A myriad of technical approaches and different em-
bolic materials have been proposed [13]. To date, n-
butyl-cyanoacrylate (NBCA) has been used for PVE and
some publications have suggested that it may be more
efficient than other embolic agents [14]. PVE with
NBCA has been widely adopted throughout the last 3
decades. However, the percutaneous access has been
nearly exclusively through the FLR as originally de-
scribed in France [4, 15].Nevertheless, access to the por-
tal vein is usually through the diseased liver that is going
to be surgically removed (ipsilateral side) when using
other embolic agents, such as particle embolics and coils
[16–20]. Furthermore, in situations that PVE with
NBCA was attempted through the ipsilateral side au-
thors have done it with the aid of either amplatzer plugs
[21, 22] or occlusion balloons [23] in order to minimize
the risk of NBCA reflux to FLR. We conducted the
present study to assessthe efficacy and safety of PVE
solely with NBCA through an ipsilateral approach.
Methods
Patients
Over a 5-year period 50 consecutive patients with pri-
mary and secondary liver cancer referred for PVE before
major hepatectomy were assessed for analysis. Inclusion
criteria were: patients with primary and secondary liver
cancer treatable by hepatectomy with a proportion of
FLR volume to the total functional liver volume (TFLV)
less than 25% orless than 40% in patients with previous
chemotherapy or hepatic cirrhosis. Exclusion criteria
were: extensive ipsilateral tumor precluding safe access
to the portal vein, unmanageable coagulopathy, extensive
extra-hepatic disease, liver abscess or infection. PVE in-
dications and details, including embolization of segment
IV, were discussed and decided previously in the weekly
multidisciplinary liver tumor board meeting. All patients
gave their written informed consent to be submitted to
PVE. The ethics committee of the Brazilian’s National
Cancer Institute (INCA) approved the study protocol
(Approval #67703317.1.0000.5274). The clinical and im-
aging records from these sequential patients were retro-
spectively gathered from the hospital archive and liver
volumetric data was generated as stated in the liver
volume section.
Study endpoints
Primary endpoint was to evaluate the efficacy of PVE
with the NBCA through an ipsilateral approach. Second-
ary end-points were accomplishment of liver surgery, pa-
tient out-come after hepatectomy and safety of the
proposed PVE technique. Efficacy was measured accord-
ing to FLR volume changes, growth rate and kinetic
growth rate and was obtained from 37 out of the 50 pa-
tients due to unavailable full imaging follow-up data (pre
or post-PVE complete set of imaging studies) in 13 pa-
tients. All other analysis refers to the total study popula-
tion (50 patients).
Portal vein Embolization
On the day of PVE patients were assigned to a hospital
bed with an anticipated 24 h hospitalization. Patients were
kept on intravenously conscious sedation (n = 33) or gen-
eral anesthesia (n = 17) depending on patient collabor-
ation and anesthesiologist preference. Except for the side
which we decided to puncture the liver, our PVE tech-
nique was accomplished similarly as reported elsewhere
[4, 15]. In brief, a non-FLR portal branch was punctured
through ultrasound guidance always avoiding tumor
transgression. A 6-F vascular sheath (Terumo, Tokyo,
Japan) was placed in the portal vein branch accessed and a
subtraction acquisition was performed through a 5F
pigtail angiographic catheter (Cook Medical, Bloomington,
IN). Selective catheterization of each second-order portal
vein branches was achieved with 5F Simmons 1 or 2 cath-
eters (Cook Medical) in the first 30 patients. Coaxial
microcatheters (2.8-F Progreat, Terumo) were additionally
used in the last 20 patients. Small boluses of n-butyl-
cyanocrylate (NBCA - Hystoacryl®, Trudell Medical
International, London, Canada) with iodized oil (Lipiodol®
Guerbet, France) in a ratio that varied from1-to-3 to 1-to-5
depending on the specific portal vein branch flow, flushed
with 5% dextrose, was used for embolization. Segment IV
embolization was also completed with glue (n = 6) except
in technically defiant or very small branches in which poly-
vinyl alcohol microparticles (100-300 μm Beadblock, Bio-
compatibles, Farnham, UK) were used (n = 4) as suggested
in previous publications [24]. A post-embolization direct
portography was obtained and the glue cast image was re-
corded. Liver parenchymal tract occlusion was performed
with the NBCA lipiodol mixture. Intravenous prophylactic
antibiotics were administered at the moment of PVE. After
hospital discharge patients were kept on oral analgesics as
needed.
Liver volumetry
A 3.0 mmor less slice thickness CT was obtained during
the arterial and portal phases with a 16-detector row multi-
slice CT scanner (Phillips, The Netherlands). On individual
slices the whole liver, the tumor and the FLR (accordingly
to previously surgical planning) were delineated with a
handheld cursor using a freely downloadable open-source
image analysis software package, OsiriX®. This open-source
PAC software system was agreed to be used since it has
been reported and validated for liver volumetric assessment
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elsewhere [25]. Once all of the regions of interest were se-
lected within one series, the volumetric calculations were
obtained using OsiriX® by multiplying surface and slice
thickness and then adding up individual slice volumes [25].
TFLV comprehended the total hepatic volume subtracted
by the tumor volume. FLR was defined as the portion of
the liver that would remain after the proposed hepatec-
tomy. The ratio between the FLR and the TFLV was calcu-
lated and defined as the FLR/TFLV ratio. The increase in
the FLR after PVE was also quantified and calculated by
the formula ((FLR post PVE - FLR pre PVE) ÷ FLR pre
PVE) as suggested in guidelines [26]. Additionally, the kin-
etic growth rate (KGR), defined as the increase in the FLR/
TFLV ratio divided by the length of time (in weeks) was
calculated [27].
Complications and patient outcome
Pain during and after PVE was assessed with 10-point
pain scales. Complications were obtained from the clin-
ical, imaging and laboratory data files and from PVE re-
ports. Complications were classified as suggested in
previous publications [15, 28]. Major complications were
defined as events that promoted significant morbidity
raising the level of medical treatments, or that prolonged
hospitalization or provoked hospital re-admissions.
Events that did not promote longer hospitalization or
did not require specific treatment were considered as in-
cidental findings (e.g., migration of minimal NBCA
fragments in the FLR) [15]. Liver enzymes and liver
function were assessed before PVE, before surgery and
in the immediate postoperative scenario. Patients’ charts
were scrutinized for submission to surgery, reasons for
precluding surgery, surgical complications, intensive care
unit admissions, transfusions, length of hospital
permanence and death. For all 50 patients included in
this study, medical reports were analyzed to the most
updated available information up to December 2016 or
death. The mean follow-up time was 23.5 months (range
1-60, SD 19.22).
Statistical analysis
Descriptive statistics including mean, standard deviation
and range were calculated for numerical variables while
absolute numbers and percentages were calculated for
categorical variables. Comparison of TFLV and FLR vol-
umes before and after PVE were performed by either
paired t-test or paired Wilcoxon rank-sum test, as ap-
propriate. Linear regression models were used to test the
association between FLR volume before PVE and FLR
volume increase after PVE and between FLR/TFLV ratio
before PVE and FLR volume increase after PVE. The as-
sociation between the use of microcatheter and the oc-
currence of complications was tested using Fisher’s exact
test and Chi-squared test.
Results
There were 37(74%) men and 13(26%) women with a
mean age of 57 years ±15 (range, 5–80 years). Colorectal
liver metastases were the most frequent tumor
(Table 1). All patients with colorectal cancer had been
previously exposed to systemic chemotherapy. No pa-
tients presented with liver cirrhosis, including the
ones with hepatocellular carcinoma. Four patients
showed biliary obstruction at presentation and were per-
cutaneously drained before (n = 3) or at the moment
(n = 1) of PVE.In 49 (98%) patients the ipsilateral ap-
proach was performed while in 1 patient both ipsilateral
and contra-lateralside punctures were performed. Mean
pain score during and after the procedure was 2.5
±2.5 points. Mean hospital stay was 1.1 days. Thirty-
eight (76%) patients had a right PVE,10 (20%) patients
had a right PVE plus segment IV and 2 patients under-
went PVE of segments VI and VII (4%), (Fig. 1).
PVE was technically successful in 49 (98%) patients.
Assisted secondary technical success was obtained in all
50 patients. PVE was technically incomplete in 1 patient
as it was necessary to repeat the procedure to achieve
full occlusion of an anterior sectorial branch that was
overlooked. Segment IV embolizations were carried out
by the ipsilateral approach in all but one patient. This
patient was submitted to a second PVE to occlude seg-
ment IV branches as decided in the tumor board meet-
ing a few days after the completion of the first PVE
procedure. Since all right portal vein branches were
already occluded we were obligated to perform segment
IV embolization through the contralateral approach. In
this case it was necessary to puncture the FLR, which
occurred uneventfully.
Regarding biliary obstruction; in 3 patients we ob-
tained a significant reduction of bilirubin levels after
Table 1 Patients’ characteristics
Number of patients 50
Age, mean (SD) 56.5(15.1)






Metastases Wilms Tumor 1 (2)
Retroperitoneal Leiomyiosarcoma 1 (2)
Chemotherapy, N (%) 39 (78)
Biliary drainage, N (%) 4 (8)
Arterial embolization, N (%) 3 (6)
Ablation before PVE, N (%) 4 (8)
SD Standard Deviation
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drainage, before performing PVE. In 1 patient the biliary
drainage was accomplished at the same moment of
PVE. For this patient we performed PVE followed by biliary
drainage at the same procedure. This tactic was imple-
mented to try to optimize the time gap between PVE and
surgery, as it is suggested in some publications [29]. Cur-
rently we first obtain an adequate biliary decompression
with undoubtful evidence of declining levels of bilirubin be-
fore we proceed to PVE in such subset of patients [30].
Volumetric liver results and laboratory values
CT assessments were performed on average 15 (range
1–22) days before PVE. Imaging interval from the day of
PVE to the post procedure volumetric CT was 32.7
±14.5 days. FLR increased froma mean value of 422 ml
±133 to 629 ml ±192 (P < 0.001) after PVE, correspond-
ing to a mean FLR increase of 52%±22% (Table 2, Figs. 2
and 3). The FLR/TFLV ratio increased from 29.6%
± 8.3% to 42.3% ± 9.8% (P < 0.001). Kinetic growth rate
was 2.98%/week ± 1.29%/week. The TFLV slightly in-
creased from 1474 ± 433 to 1531 ± 460 after PVE did
not reach statistical significance (P = 0.070). Laboratory
values showed no significant changes of measured param-
eters at 4–5 weeks after PVE when compared with mea-
surements before PVE (Table 2).
Association of factors with FRL increase after PVE
A negative association was observed between FLR vol-
ume and increase in the FLR after PVE (Beta = −0.06,
P = 0.017, Fig. 4 top) and between the FLR/TFLV ratio
before PVE and the increase in the FLR after PVE
(Beta = −1.29, P = 0.002, Fig. 4 bottom).
Complications
Of the 50 patients submitted to 52 PVE procedures
three experienced major complications (5.7%): signifi-
cant migration of NBCA fragments to the FLR (n = 1), a
subcapsular biloma (n = 1) and FLR portal vein stenosis
due to NBCA fragment dislodgment associated with
cholangitis (n = 1) and. The latter patient was a 74 year-
old male patient with cholangiocarcinoma submitted to
percutaneous biliary drainage and PVE at the same time.
During catheter manipulation there was glue dislodg-
ment to the main left portal vein creating a stenosis.
This patient showed the lowest rate of FLR increase in
our study (20%). He was re-admitted to the hospital
Fig. 1 a Glue cast at the end of PVE. Glue cast at the end of PVE in an
8 year-old boy with right-liver Hepatoblastoma showing satisfactory
NBCA deposition in the right portal branches. b Post-embolization
direct portography. Post-embolization direct portography in the same
patient showing occlusion of the right portal branches and good flow
to the left portal vein
Table 2 Liver volumetry before and after PVE
PVE segments, N (%)
Right plus IV PVE 10 (20)
Right PVE 38 (76)
Segments VI and VII 2 (4)
PVE approach, N (%)
Ipsilateral 49 (98)
Ipsi and Contra-lateral 1 (2)
Microcathether, N (%) 20 (40)
Glue: Lipidol ratio (range) 1-3 to 1-4
Before PVEa
Total functional liver volume, mL, mean (SD) 1473.57 (432.78)
Future liver remnant, mL, mean (SD) 421.95 (132.54)
After PVEa
Total functional liver volume, mL, mean (SD) 1531.24 (459.77)
Future liver remnant, mL, mean (SD) 628.97 (191.64)
FLR increasea, % 51.67 (21.81)
FLR ratio increasea, % 12.73 (4.8)
Kinetic growth ratea, %/week 2.98 (1.29)
aData available for 37 patients
SD Standard Deviation
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25 days after PVE with cholangitis and deceased 7 days
afterwards due to refractory sepsis. Solely in this patient
the complication precluded liver surgery (Fig. 5a and b).
Nine patients presented incidental findings or adverse
events: 5 cases of very mild and minimal NBCA
migration to the non-embolized liver, 1 case of small
NBCA fragment migration to the right hepatic vein and
3 cases of nauseas and vomiting. All these patients with
minute fragments of glue in the FLR or in the right hep-
atic vein presented satisfactory hypertrophy levels
Fig. 2 a Computed tomography before PVE. A contrasted portal phase computed tomography before PVE in a 67 year-old female with colorectal
cancer and liver metastasis. b Direct portography. Direct portography depicting normal portal vein anatomy during PVE. c Glue cast. Glue cast in
the right portal branches at the end of PVE showing satisfactory distribution of the NBCA-lipiodol mixture. d Computed tomography 30 days after
PVE. Portal venous phase computed tomography 30 days after PVE showing an important hypertrophy of the left liver. e and f Computed
tomography volumetry after PVE. Computed tomography volumetry yielded a FLR increase of 44% and a FLR/TFLV ratio expansion from 34% to
47% after 30 days. g Liver specimen after right hepatectomy. Liver specimen after right hepatectomy showing glue in a right portal vein branch
from the previous portal vein embolization. h 3-year post-operative computed tomography. Post-operative portal venous phase computed
tomography 3 years after PVE with a good remnant liver volume
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probably secondary to their very small size and non-
occlusive arrangement [15].
Complications and the use of microcatheters
There were no major complications, regarding NBCA,
in patients where PVE was achieved with a microcath-
eter. Moreover incidental findings and adverse events
were much more common in patients that a microcath-
eter was not used (n = 7) than in patients in whom it
was adopted (n = 2). This analysis did not reach statis-
tical significance (p = 0.189).
Surgical outcomes
Thirty-four patients were taken to the operating room
although 3 patients presented intraoperative disease pro-
gression that prohibited liver resection. Thirty-onepatients
eventually were submitted to hepatic surgery (62%). The
executed liver resection procedures were as follows: right
hepatectomy in 19 patients, right hepatectomy extended
to segment IV in 8 patients, right hepatectomy extended
to segment IV with resection of the caudate lobe and left
portal vein reconstruction in 1 patient, resection of seg-
ments VI and VII in 2 patients and Associating Liver
Partition and Portal vein Ligation for Staged hepatectomy
(ALPPS) in 1 patient. Post hepatectomy complications
Fig. 3 Graph showing increase in TFLV and FLR volume. Graph
showing slight increase in the TFLV after PVE (top graph)
and significant increase in FLR volume 1 month after PVE using
NBCA (P < 0.001 – bottom graph)
Fig. 4 Graph showing small FLR superior growth. Graph showing
the concept that smaller FLRs will grow most after PVE through the
negative association observed between FLR volume (top) and FLR/
TFLV ratio (bottom) and increase in the FLR after PVE
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comprised bile leak or fistula or biloma (n = 3), pneumo-
nia (n = 1), intraoperative hepatic bleeding (n = 3), sepsis
(n = 1), subcapsular abscess (n = 1) and liver insufficiency
(n = 1). Hospital stay was 9.97 days on average (range 3 to
56 days). Three patients needed blood transfusion.
Thirteen patients eventually died (four patientswithin
30 days of hepatectomy - three from liver hemorrhage
and one from a severe pneumonia). Sixteen patients were
not taken to surgery due to disease progression (n = 14),
cholangitis, liver insufficiency and death (n = 1) and
uncontrolled comorbidities (n = 1).
Discussion
Liver surgery has certainly evolved in the last decades [5,
10] and for patients with less than adequate FLR volume
before hepatic resections PVE is the procedure of choice
in most hepatobiliary treatment centers [31]. Different
PVE techniques and approaches have been described
and numerous embolization materials have been tested
to stimulate remnant liver growth [3, 13, 32]. Analyses
of the induced hypertrophy of PVE with NBCA using
animaland afterwards human subjects showed its greater
capacity compared to that of PVE with other embolic
materials [14, 32] that might be related to the provoked
periportal inflammatory response [4, 32]. Patients in the
present study presented a substantial degree of FLR hyper-
trophy and increase in the FLR/TFLV ratio in accord-
ance with previously published data including studies
that compared NBCA glue with microparticles and coils
[14, 22, 33]. The mean absolute FLR volume increase
of 52% and the FLR/TFLV ratio expansion of 12% are
superior to the published hypertrophy results in studies
using other embolic agents than NBCA [14, 21, 34, 35].
Previously reported figures for PVE using NBCA, polyvi-
nyl alcohol particles (PVA) plus coils/vascular plugs,
gelatin sponge, PVA alone and fibrin glue are in the
range of 47%-79%, 24%-54%, 17%-37%, 24%-32%
and 27%-31% of FLR volume increase respectively [4, 24,
36, 37].
Another important and very discussed technical point
in PVE is which side should be elected for the punc-
ture, the contralateral, achieved through an access of the
FLR’s peripheral portal branch, or the ipsilateral, attained
by the puncture of the portal vein that will be removed
in the near future hepatectomy. In the contralateral ap-
proach, developed in France [15, 38, 39], there is a po-
tentially easier catheterization of the right portal
subdivisions and the possibility to use smaller catheters
[15] with the drawbackof potential harm to the FLR’s
portal vein. The ipsilateral approach, in contrast, avoids
puncture of the FLR but has a trickier catheterization
[40]. In a systematic review that included studies from
1990 to 2011 [33], the ipsilateral approach accounted for
55% (n = 963) of all PVE procedures but in only 3% (28
procedures) the glue-lipiodol mixture (without coils nor
particles nor amplatzer plug) was adopted as their sole em-
bolic material. Moreover, the authors from this systematic
review argued that it would be hard to manipulate glue
from the ipsilateral side. Albeit we agree that PVE with glue
requires extra caution, is a technically demanding proced-
ure [24], and has a steep learning curve, the present study
suggests that it can be performed through an ipsilateral ap-
proach. To our knowledge, this is one of the largest PVE
series employing solely NBCA-lipiodol mixture as the em-
bolic material through an ipsilateral approach.
These results show that the initial FLR volume and
FLR/TFLV ratio were predictive factors for FLR hyper-
trophy after PVE, indicating that patients with lesser
FLR volume or minor FLR/TFLV ratios at presentation
will be the ones we can expect the greatest FLR enlarge-
ment. This association has been previously described in a
study analyzing predictors of hypertrophy of the FLR
after PVE in a non-cirrhotic population [24]. In cirrhotic
patients with primary liver tumors this analysis was also
performed and likewise similar results were shown [41,
Fig. 5 a Portography showing the dislodged NBCA. Direct
portography during PVE showing the dislodged NBCA fragment in
the left portal vein (red arrow). b CT showing dislodged NBCA.
Contrasted-enhanced CT 4 weeks after PVE showing the NBCA fragment
in the left portal vein (red arrow). This patient presented a 20% FLR
hypertrophy but deceased due to fulminant cholangitis before surgery.
(dark-blue arrow - Biliary drain trajectory in the liver)
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42]. This correlation was also demonstrated in the surgi-
cal series that scrutinized liver regeneration and influen-
cing factors. The general conclusion is that liver
regeneration rate after resection is proportional to the
volume of hepatic parenchyma removed at surgery
whether or not liver dysfunction is present [43, 44]. As
far as expectations and indications go for PVE these
findings have direct influence in its daily practice. Since
the degree of hypertrophy is inversely associated with
the initial FRL volume, one should reaffirm PVE indica-
tion even for very small FLR volumes [24].
Of all complications associated with PVE recorded in
our sample, only one precluded future liver surgery. This
latter patient presented a stenosis of the left portal vein
through the dislodgment of a glue fragment ensued near
the completion of PVE and deceased 32 days after that
from cholangitis and liver insufficiency. In this case we
could have tried to pull the NBCA fragment back into
the right portal vein as shown elsewhere [45], even
though at that moment we did not have the appropri-
ated material. While it is not stated in PVE guidelines or
quality improvement statements [26] we currently main-
tain adequate retrieval materials such as snares and
angioplasty balloons at our interventional radiology de-
partment, principally when dealing with embolic mate-
rials such as glue. It is also advisable to get satisfactory
bilirubin clearance before PVE instead of performing
both percutaneous biliary drainage and PVE procedures
at the same time [29] as recommended in guidelines
[26]. Particular attention should be devoted to avoid
FLR glue migration since it can preclude liver surgery.
When comparing complication rates between the groups
with and without additional use of microcatheters there
were no cases of major NBCA migration or dislodgment
with its use and it was suggested that glue migration
might be avoided with this coaxial technique. This dif-
ference did not reach statistical significance probably
due to the small sample size. Additionally, the interpret-
ation of this finding also suffers from the allocation of the
use of the microcatheter, which was not random. We be-
lieve the use of microcatheters associated with the ad-
ministration of small glue aliquots (e.g. 0.3 mL) in
between abundant flushing with dextran or glucose 5%
[26], is highly advisable when performing PVE with
NBCA through an ipsilateral approach. Technical ad-
vises have been systematically addressed in the PVE
NBCA publications, alerting for the extra care towards
the end of the procedure where most of the targeted
portal branches are already occluded, the few branches
left usually demonstrate slow flow and complications,
particularly embolic material reflux to the left portal
vein, might occur [15].
The technical success rate (98%) and the clinical success
rate of PVE (96%) in the present study were high and in
accordance with the previous reported results [33]. Two
patients (4%) presented insufficient hypertrophy after PVE
and one of them could not be submitted to the planned
surgery because of the associated development cholangitis
and liver insufficiency. The other patient had a FLR before
PVE which accounted for 17% of the TFLV and despite
the significant hypertrophy of 76% and an increase to 30%
in the FLR/TFLV ratio the liver surgeon decided to per-
form an ALPPS procedure to amplify FLR growth. The
ALPPS was performed in May 2014 and this patient is
currently on follow-up with no evidence of cancer related
disease. In this series thirty-one patients (62%) were sub-
mitted to liver resections. One patient presented signs of
liver failure within 30 days from hepatectomy with poster-
ior convalescence. Out of the 31 patients submitted to
liver surgery 18 (58%) are alive with no signs of hepatic in-
sufficiency. Our 62% liver resection rate is below the usual
published statistics for PVE in which approximately 70%
to 80% of the originally planned liver resections after PVE
are performed [33, 46]. In our group the vast majority of
patients were not taken to liver resection after PVE due to
disease progression. While this is the most frequent cause
of not performing hepatectomies after PVE [33, 47], some
of our cohort patients also suffered from inadequate
long waiting periods for surgery after PVE due to
local institutional impairments which might influence
disease progression. Besides that, during PVE-induced
liver regeneration, disease progression may be second-
ary to undetectable pre-existing tumor growth, and
PVE may, consequently, perform as a surrogate
marker of cancer biology, removing patients that are
not suitable for surgery [46]. Notwithstanding tumor
progression, FLR growth following PVE would have
been sufficient to permit the planned hepatic resec-
tion in all but one of these patients.
This study has limitations. This was a retrospective
study occurring over a period of five years and as such
it is plausible that the improved patient selection for
PVE and radiologists’ experience gained over the years
could result in better outcomes. The data collection
and extraction relied primarily on medical charts. The
small sample hindered us from exploring other factors
that might be linked to greater FLR increase. A strength
of this study was the relative homogeneous patient
population conceded only by non-cirrhotic patients
which otherwise could have confused our hypertrophy
results because of cirrhosis regeneration recognized
variances [48]. Furthermore, even though NBCA is one
of the main embolic agents used worldwide for PVE
and it is suggested that it induces the highest FLR
growth, its administration has been reported almost ex-
clusively from the contralateral side. This study was
able to show that it is possible to use NBCA for PVE
without approaching the FLR.
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Conclusions
This study suggests that PVE with NBCA through an
ipsilateral puncture is an effective procedure to permit
major hepatectomies in patients with a small FLR.
Meticulous attention is needed especially near the end
of the embolization procedure to avoid complications.
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